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ABSTRACT
Background: No study has combined tumour and clinical covariates for survival 
to construct an individual risk-profile for overall survival (OS), time to progression 
(TTP), and survival after progression (SAP) in patients with HPV+ and HPV– 
oropharyngeal squamous cell carcinoma (OPSCC). Based on the largest-to-date, 
unselected, population-based cohort of patients diagnosed with OPSCC, we performed 
a comprehensive analysis of long-term OS, TTP, and SAP and constructed novel 
nomograms to evaluate patients' prognoses. 
Results: At a median follow-up of 4.0 years (range: 0.8–15.8 yrs.), 690 deaths 
were recorded. The 5-year OS, TTP, and SAP for the HPV+/p16+ subgroup were 
77%, 82%, and 33, vs. 30%, 66%, and 6% for the HPV–/p16– group (P < 0.01). 
376 patients failed to maintain disease control with a median TTP of 13 months in 
the HPV+/p16+ subgroup vs. 8.5 months in the HPV–/p16– subgroup (P < 0.05). 
HPV combined with p16 status remained one of the most informative covariates in 
the final Cox regression model for OS, TTP, and SAP. 
Methods: We included all patients diagnosed with OPSCC (n = 1,542) between 
2000–2014 in Eastern Denmark. Survival rates were estimated by the Kaplan-Meier 
method. A multivariate Cox regression model was used to construct predictive, 
internally validated nomograms. 
Conclusion: The HPV+/p16+ subgroup had improved OS, TTP, and SAP compared 
with other combinations of HPV and p16 after adjusting for covariates. Nomograms 
were constructed for 1-, 5- and 10-year survival probability. Models may aid patients 
and clinicians in their clinical decision making as well as in counselling, research, and 
trial design.
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INTRODUCTION
In the Western world, the main risk factor for 
developing oropharyngeal squamous cell carcinoma 
(OPSCC) is infection with high-risk human papillomavirus 
(HPV); while, a smaller proportion is related to the 
high consumption of alcohol and smoking tobacco. 
Patients with HPV-associated OPSCCs have improved 
survival, which may be related to a different mutational 
profile [1, 2], histopathology [3], and clinical features 
[4]. The first reports of improved survival for HPV-
positive (HPV+) OPSCCs were published in the early 
2000’s [5, 6].Shortly after, p16 (a surrogate-marker for 
HPV- infection) was demonstrated to have prognostic 
value [7, 8]. The importance of HPV and p16 has since 
been confirmed, and the combination (e.g. HPV/p16-
status) has shown better prognostication [9]. However, 
long-term results are missing for overall survival (OS), 
time to progression (TTP), and survival after progression 
(SAP), especially their relationship to clinico-pathological 
characteristics from a large, population-based cohort. 
Progression is a strong predictor of survival in 
patients with OPSCCs. The subgroup of patients who are 
HPV and p16-positive have a lower risk of recurrence 
and improved SAP compared with patients without 
HPV/p16 [10–12]. These findings are based on selected 
patients from small cohort-studies examining only 
p16 or HPV without a detailed account of progression. 
Therefore, HPV+ OPSCC may have an increased OS 
due to a better response to salvage therapy (i.e. SAP). 
A nomogram is a graphic demonstration of a statistical 
model for calculating the cumulative effect of weighted 
variables on the probability of a particular outcome, 
and enables continuous estimation of the probability of 
specific outcomes (i.e. death or progression). Furthermore, 
they can combine multiple independent variables while 
considering the prognostic weight for each variable when 
calculating the probability of an outcome. Although 
nomograms have been developed to predict clinical end-
points for patients with several types of malignancies, to 
the best of our knowledge, this is the first study addressing 
OS, TTP, and SAP in OPSCCs [13–17].
To avoid selection-bias, we aimed to include all 
patients diagnosed with OPSCC in the Eastern part of 
Denmark, which has an approximate population size of 
2.4 million inhabitants. The cohort is well described and 
includes detailed information on both tumour (HPV, p16, 
stage, site) as well as clinical characteristics (follow-up, 
treatment, progression) with virtually no patients lost to 
follow-up. The primary aim was to identify tumour- and 
patient-factors associated with OS, TTP, and SAP. Due to 
our unique, complete population-based cohort spanning 




A total of 1,542 patients diagnosed with 
OPSCC between 2000–2014 were included, and their 
characteristics are summarized in Table 1 with univariate 
hazard ratios for OS. The majority of patients were males 
(72%), with a median age of 60 years at diagnosis, and 
typically presented with tumours in an advanced nodal 
stage, but with small primary tumours (Table 1). Of 
the total cohort, 54% were stage III or IV, 61% had 
T1 or T2 primary tumours, and 60% had N2 or N3 
nodal classification (Table 1). The median follow-up 
for patients alive at the last date of follow-up was 4.0 
years (range, 0.8 to 15.8 years). Tobacco use was high 
with a median number of pack-years of 27 (mean 30). 
Subsequently, we examined which of the variables were 
correlated (Figure 1D). It was observed that the subgroup 
of patients with an HPV+/p16+ tumour correlated 
with: a shorter smoking history, higher N-stage, better 
performance status, lower T-stage, and younger age 
(Figure 1D).
Univariate and multivariate analysis of factors 
influencing overall survival
In the OS analysis, 1,524 patients (18 were 
lost to follow-up) were included, with a total of 690 
deaths. In the total cohort, 1,336 patients were treated 
with curative regimes; of these patients, 543 died 
during follow-up. The subgroup of HPV+/p16+ had 
a markedly better prognosis compared with the other 
combinations of HPV/p16 (Table 1 and Figure 1A) 
(p < 0.05). Other factors significantly associated with a 
poorer OS in the univariate analysis were: pack years of 
smoking, treatment, tumour location, and T, N, and M 
classification (Table 1). We subsequently constructed 
a multivariate Cox regression model to examine 
which factors independently predicted OS. The HPV/
p16 status was an independent predictor for OS, even 
when adjusted for T-stage, N-stage, treatment, smoking 
history, age, and performance status (Supplementary 
Table S1). To better illustrate any excess mortality in 
the HPV+/p16+ and HPV-/p16- subgroups, Kaplan-
Meier survival curves were compared with the mortality 
rates of the background population matched for age, 
gender, and calendar period (Figure 1E and 1F). 
Interestingly, patient with stage T1-T2 tumours in the 
HPV+/p16+ subgroup had almost no excess mortality 
compared with the background population (Figure 1E), 
which was in stark contrast to the HPV−/p16− subgroup 
(Figure 1F).  
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Univariate and multivariate analysis of factors 
influencing time to progression 
In total, 376 patients experienced a progression, with 
153 (19%) in the HPV+/p16+ subgroup vs. 182 (36%) 
in the HPV-/p16- subgroup (P < 0.01). The subgroup of 
HPV+/p16+ had a significantly longer TTP compared with 
the other combinations of HPV/p16 (Figure 1B) (P < 0.05). 
The median TTP for the total cohort was 9.7 months. 
The median TTP was 13 months for the HPV+/p16+ 
subgroup and 8.5 months (P < 0.05) for the HPV−/p16− 
subgroup. Median time to loco-regional progression was 
Table 1: Patient characteristics and their relationship to overall survival
Footnote: The hazard ratios for age, year of diagnosis, and pack years represents the hazard ratio per year increase. RT: 
radiotherapy. BSCC: Base of tongue squamous cell carcinoma. STSCC and NSTSCC: Specified- and non-specified tonsillar 
squamous cell carcinomas.
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Figure 1: Kaplan-Meier curves for (A) overall survival, (B) time to progression, and (C) survival after progression. 
Correlation heatmap between variables (D). Comparison between survival in an age- and gender-matched background population and 
the HPV+/p16+ subgroup (E) and the HPV-/p16- subgroup (F) based on T classification of tumours.
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7.6 months for the HPV+/p16 subgroup and 7.4 months 
for the HPV−/p16− group. The corresponding figures for 
distant progression were 18 and 11 months, respectively, 
(P < 0.05). The univariate analysis of factors influencing 
TTP included: pack years of smoking, HPV/16 status, and 
T, N, and M classification of tumours (Supplementary 
Table S2). A multivariate Cox regression model identified 
HPV/p16 status as an independent predictor of TTP with 
a hazard ratio of 3.0 (95% CI: 2.3–3.8) in the HPV−/p16− 
subgroup compared with the HPV+/p16+ subgroup, after 
adjustment (Supplementary Table S3).
Univariate and multivariate analysis of factors 
influencing survival after progression
The median SAP was 13 months in the HPV+/
p16+ subgroup vs. 6 months in the HPV-/p16- subgroup 
(P < 0.05). The HPV+/p16+ status also independently 
influenced SAP positively with a hazard ratio of 2.2 
(95% CI: 1.6–2.9) compared with the HPV–/p16– 
subgroup (Supplementary Table S4), when adjusted 
for other significant covariates. Performance status and 
progression location also independently influenced SAP 
(Supplementary Table S4). 
Predictive nomograms
Nomograms (Figure 2A and 2B) were constructed 
to predict survival using the independent covariates 
identified in the multivariate Cox regression models. The 
median total points for the 1,523 patients used to fit the 
multivariate Cox model for OS was 101 (range, 0–421). 
The nomogram is used by totalling the points identified 
on the top scale for each independent covariate which is 
identified on the total points scale to identify the estimated 
median survival time (years) and the probability of 1-, 5- 
and 10-year survival.
The bias-corrected concordance index for this 
nomogram was 0.79 based on the bootstrap validated Cox 
model. The calibration curve (Supplementary Figure S1) 
illustrates how the predictions from the nomogram compare 
with actual outcomes. The corresponding information for the 
nomogram for TTP can be found in Supplementary Figure S2.
Prognostic index
A simplified prognostic index was constructed for the 
5-year OS using seven independent prognostic factors. The 
index score is based on the sum total of factors, with points 
given for each of the following: treatment, HPV/p16-
status, age, pack years, T-status, N-status, and performance 
status. Risk is assigned as follows: index score 0 to 4, low 
(≥ 80% probability of surviving 5 years); index score 5 to 
7, intermediate (< 80% and > 20% probability of surviving 
5 years); and index score 8 or greater, high risk (≤ 20% 
probability of surviving 5 years) (Table 2). 
DISCUSSION
This study included the largest-to-date collection 
of 1,542 OPSCCs from a consecutive, population-based, 
non-selected cohort and assessed OS, TTP, and SAP as 
well as their relation to multiple clinico-pathological 
characteristics. From these results, we constructed and 
internally validated nomograms to predict OS and TTP. 
Furthermore, we established a simplified prognostic 
index based on the independent covariates for OS for 
use in categorizing patients into low-, intermediate-, and 
high-risk groups. Besides being useful for interpretation 
of the underlying Cox model, the nomogram combines 
independent prognostic factors and considers the 
importance of each on the probability of survival and 
progression. The prognostic models we present may 
facilitate discussions in clinical settings and aid in 
identifying low-risk patients that could be candidates 
for de-escalation therapy, as well as high-risk patients 
eligible for new clinical trials. In particular, HPV+/
p16+ patients with T1-T2 tumours should be considered 
candidates for de-escalation therapy, as we demonstrated 
their survival is similar to the background population, and 
this would avoid the morbidity associated with therapy. 
Notably, at least nine de-escalation treatment trials are on-
going or finishing [18]. Our nomograms are likely to be 
applicable to these and future trials, as we reported similar 
5-year survival or progression rates as studies in North 
America;[19–21] Western [22–24], Southern [25], and 
Northern Europe [6, 26]; Australia [27]; and China [28].
An estimated 10% of all head and neck SCCs 
are p16+, but HPV– caused by alternative cellular 
misconfigurations leading to p16-overexpression.[29, 30] 
Therefore, it is suboptimal to include patients in de-
escalation trials based on evaluation of a single biomarker 
(i.e. HPV or p16 alone) due to the risk of misclassification 
of tumours and thereby misallocation of patients with an 
undesired prognosis. [31, 32] One of the main findings in this 
study includes the identification of HPV+/p16+ as an important 
and independent predictor for improved OS, TTP, and SAP. 
Importantly, even though the subgroup of HPV+/p16+ patients 
was more likely to have a shorter smoking history and a better 
performance status, even when adjusted for these covariates, 
HPV+/p16+ was a significant and strong predictor for OS. The 
calibration for this model was robust and could explain 79% 
of the observed variability in OS in the cohort. Our findings 
are in accordance with similar studies addressing survival and 
progression in HPV+ or p16+; although, we present the first 
results of a population-based cohort with long-term follow-up. 
While another smaller study in a region with low HPV-
prevalence (below 20%) constructed nomograms for OS 
and TTP in OPSCC, this study was not population-based 
and did not address SAP.[33] Furthermore, this study did not 
convincingly demonstrate which patients were lost to inclusion 
and follow-up, resulting in less robust external validity. 
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Table 2: Prognostic index for overall survival
Points 0 1 2 3
Treatment RT and chemotherapy RT Palliative NA No treatment
Age 0–44 45–64 65-89 90 and above NA
HPV/p16 HPV+/p16+ HPV–/p16+ HPV–/p16– or HPV+/p16– NA NA
T classification T1 T2-T3 T4 NA NA
N classification N0 N1-N2 N3 NA NA
Pack years 0–59 59–179 180 and above
Performance status 0–1 2–3 NA NA 4
Footnote: It is possible to obtain between 0 and 19 points. Low-risk is from 0–4 points (≥ 80 % risk of being alive after 
5 years), medium risk 5–7 points (between < 80 and > 30% chance of being alive after 5 years), and high-risk > 7 points 
(≤ 30% change of being alive after 5 years).
Figure 2: Nomogram for overall survival (A) and time to progression (B). The nomogram is used by totalling the points 
identified on the top scale for each independent covariate. The total points scale is used to identify the estimated median survival time 
(years) and the probability of 1-, 5-, and 10-year survival.
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Our nomograms support the latest AHR-stage 
classification proposed by O’Sullivan et al. [34] and 
comply with the notion that T1–T2 and N0–N2 show 
significantly better OS, TTP, and SAP compared with 
≥ T3 and ≥ N3 tumours, indicating that down-staging 
of N-classified OPSCCs is reasonable. Noticeably, our 
findings, in contrast to O’Sullivan et al, include both 
HPV and p16 status and patients with distant disease. Our 
models encourage further studies to better understand 
whether all N-classified tumours are eligible for down-
staging. Although our findings rely on a population-based 
cohort and selection-bias is minimized, the nomograms 
have certain limitations. It would be most appropriate to 
apply the model as the last step in a clinical setting, and 
the models are not necessarily applicable for changing 
patients’ decisions not to accept further treatment since we 
do not know her/his response to therapy. With respect to 
accuracy, the CIs at the various predicted probabilities of 
recurrence should be considered if using these nomograms 
in clinical settings. Although this model is internally 
validated, it could be strengthened by external validation, 
e.g. in similar population-based cohorts. Future work 
might focus on validating our results and incorporating 
additional prognostic factors including robotic, curative 
surgery, and specific salvage treatment for relapsed 
disease as well as further outcome measures such as time 
to treatment or to pathological evaluation.
MATERIALS AND METHODS
We included patients diagnosed with OPSCC in 
Eastern Denmark between 2000–2014. The reasons 
for exclusion are illustrated in Figure 3. We targeted all 
patients diagnosed with OPSCC in the Eastern part of 
Denmark cohort with detailed information on tumour 
(HPV, p16, stage, site) and clinical characteristics (follow-
up, treatment, progression). Using the unique resident-
code from the Danish Civil Registration System, we linked 
two national registries, the prospectively maintained 
Danish Head and Neck Cancer Group (DAHANCA) [35] 
database and the Danish Pathology Data Registry (DPDR) 
[36], to identify patients. Patient-data were retrieved from 
these databases as well as from medical records. The 
patient cohort from 2000 to 2010 has previously been 
described [37, 38].
Tumour-site, histology, tumour-grade, 
HPV- PCR, and p16 immunohistochemistry 
An H&E-stained section of each tumour was 
reviewed by an expert head and neck pathologist. Based 
on the finding of tissue-specific structures and clinical 
information, tumours were divided into base of tongue 
squamous cell carcinoma (BSCC) and specified- and non-
specified tonsillar squamous cell carcinomas (STSCC and 
NSTSCC). The latter was according to the certainty of 
origin. The pathologist validated the diagnosis of OPSCC. 
The p16 staining was considered positive if there was a 
strong and diffuse nuclear and cytoplasmic reaction in 
more than 75% of the tumour cells [39]. The HPV DNA-
PCR was performed with DNA isolated from FFPE 
tumour sections. Methods for immunohistochemistry and 
HPV-PCR have previously been described [37, 38].
Overall survival, time to progression, and 
statistics 
The date of the last follow-up was the 1st of 
November 2015. The OS was defined as the time 
from diagnosis of OPSCC to death due to any cause. 
Data on vital status (death) stems from the real-time, 
national, patient-administrative Green System (GSOpen). 
Progression was only considered if it was biopsy-
verified. Data on progression stem from the DPDR. The 
TTP was defined as the time from diagnosis of OPSCC 
to time of progression at any site. In the analysis of TTP, 
patients were censored either at the last date of follow-
up or at time of death. Patients alive at the last date of 
follow-up were censored in survival analyses for OS and 
SAP. The date of diagnosis was used to reflect the date 
of treatment, since the vast majority of Danish patients 
initiate treatment within 1 month [40, 41]. The SAP 
was defined as the time from progression to death due 
to any cause. Curative radiotherapy regimens consisted 
of 66–68 GY, divided into 33–34 fractions given 6 
days a week. From 2007, stage III-IV patients were 
offered concomitant cisplatin, if tolerated. Covariates 
available for adjustment are described in Table 1. The 
following variables were coded as continuous variables 
in the survival analyses: age and year of diagnosis. 
The remaining variables were coded as categorical 
variables unless otherwise stated. Data on smoking 
(20 cigarettes per day for 1 year = 1 pack year) were 
retrieved from the DAHANCA database or medical files. 
Kaplan-Meier curves were used to illustrate survival 
differences and significant differences were assessed 
with log-rank tests. Hazard ratios for death, OS, and 
TTP were calculated by univariate Cox-regression with 
log-rank tests for each parameter (Table 1). To evaluate 
which covariates independently influenced survival, we 
performed multivariate cox regression analyses with the 
same factors used in the univariate analyses (Table 3 
and Supplementary Tables S2 and S3) with backward 
elimination, until only significant factors remained. The 
stopping rule in the backward elimination of factors 
was based on Akaike’s  Information Criteria, with the 
statistics based on the pooled residual chi-square of the 
model with the R package rms and the function fastbw 
[42]. The models were internally validated with 200 
bootstrappings. The difference in Somers’ D between 
the training and test set was used to evaluate the 
optimism in the predictive accuracy (i.e. a measure of 
Oncotarget71768www.impactjournals.com/oncotarget
the difference between observed and predicted values). 
Somers’ D can range from –1 (all pairs disagree) to 1 
(all pairs agree) and can be converted to the more well-
known AUC via the following formula, AUC = Dyx/2 
+ 0.5. The calibration of the models was subsequently 
tested using the rms package in R. To test whether the 
assumption of proportional hazards was violated, we 
plotted Schoenfeld residuals for the univariate analyses 
[43]. Additionally, the multivariate models for survival 
were examined for violations of the proportional hazards 
assumption with the function cox.zph. None of the final 
models violated the proportional hazards assumption. 
To test for correlations between the covariates, we 
used Spearman’s rank correlation (Figure 1D) [44]. 
The analysis comparing survival in the cohort with the 
background population was performed for each year of 
observation according to the Kaplan-Meier survival rates 
in the cohort. The survival analysis for the background 
population was performed for a gender and age-matched 
population in the same calendar-years as the cohort with 
mortality figures from the Danish National Department 
of Statistics (http:\\www.statistikbanken.dk/statbank5a/
default.asp?w=1344). Missing data were left out of 
the analysis, and variables with missing values are 
illustrated in Table 1. A p value < 0.05 was considered 
significant. Data were analysed with SPSS version 
23 (SPSS Inc., Chicago, IL, USA) and R statistics 
version 3.03.
Figure 3: CONSORT flow-diagram
Oncotarget71769www.impactjournals.com/oncotarget
Validation and calibration of multivariate cox 
regression models
When performing multivariate analysis of survival, 
it is of interest to examine how well the models can 
explain the variation in survival observed in the cohort. 
The Somers’ D for the final model for OS was 0.60, which 
corresponds to an AUC of 0.80. This was validated with 
bootstrapping to prevent possible over fitting using the 
Somers’ D rank correlation for the predicted log hazard 
and observed survival time. The optimism in the model 
was 0.0064, and the expected bias-corrected AUC was 
0.79, suggesting that the model was not over fitted. Finally, 
the models were evaluated for calibration accuracy in 
predicting the probability of surviving 5 years. This was 
performed with bootstrapping to estimate the optimism 
from the models for how the predicted 5-year survival 
estimates compared with the observed survival estimates 
(Supplementary Figure S1).  The corresponding AUC and 
optimism in the multivariate Cox regression model for 
TTP were 0.68 and 0.010, respectively, and the calibration 
curve is shown in Supplementary Figure S2.
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Table 3: Independent covariates for overall survival in the multivariate Cox regression model
Hazard ratio for death Lower CI Upper CI P
T classification
T1 Ref
T2 1.55 1.13 2.11 0.0060
T3 2.32 1.69 3.19 < 0.0001
T3 3.59 2.52 5.11 < 0.0001
N classification
N0 Ref
N1 1.59 1.17 2.17 0.0034
N2 2.00 1.54 2.60 < 0.0001
N3 3.59 2.48 5.19 < 0.0001
Treatment
Radiotherapy Ref
Chemoradiotherapy 0.7 0.6 0.9 0.0042
Palliative 2.4 1.7 3.5 < 0.0001
No treatment 7.2 4.2 12.1 < 0.0001
HPV/p16
HPV+/p16+ Ref
HPV+/p16– 2.5 1.8 3.7 < 0.0001
HPV–/p16+ 2.1 1.4 3.0 0.0001
HPV–/p16– 3.4 2.7 4.3 < 0.0001
Age 1.03 1.01 1.04 < 0.0001
Pack years 1.005 1.002 1.008 0.0015
Performance score
0 Ref
1 1.3 1.1 1.7 0.0105
2 2.1 1.5 2.9 < 0.0001
3 1.6 0.9 2.8 0.0905
4 7.9 2.1 29.9 0.0024
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